Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
J.R. Hampton,D. J. Van Veldhuisen,Franz X. Kleber,Alan J. Cowley,A Ardia,P Block,A Cortina,L Cserhalmi,Ferenc Follath,G Jensen,J Kayanakis,Kong I. Lie,Giuseppe Mancia,A M Skene +13 more
Reads0
Chats0
TLDR
The finding that antiarrhythmic treatment was a significant predictor of increased mortality in ibopamine-treated patients may be important, but exploratory analyses must be interpreted with caution.About:
This article is published in The Lancet.The article was published on 1997-04-05 and is currently open access. It has received 338 citations till now. The article focuses on the topics: Ibopamine & Heart failure.read more
Figures
Figure 1: Trial profile Continued=patients who took study medication until end of study or who died within 14 days of withdrawal. Discontinued=patients who were withdrawn from treatment and did not die within 14 days of last tablet, or who were not formally withdrawn but had not taken study medication within 14 days of end of study. 
Table 4: Univariate analysis of 1-year mortality in selected subgroups of patients in whom excess mortality was 
Table 2: Causes of death 
Figure 2: Kaplan-Meier survival curves for ibopamine and placebo groups
Citations
More filters
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: In this article, Anderson et al. proposed a new FAHA Chair, Jeffrey L. Anderson, MD, FACC, FAHA, Chair-Elect, Alice K. Jacobs et al., this article and Biykem Bozkurt.
Journal ArticleDOI
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
Sharon A. Hunt,William T. Abraham,Marshall H. Chin,Arthur M. Feldman,Gary S. Francis,Theodore G. Ganiats,Mariell Jessup,Marvin A. Konstam,Donna Mancini,Keith Michl,John A. Oates,Peter S. Rahko,Marc A. Silver,Lynne W. Stevenson,Clyde W. Yancy,Elliott M. Antman,Sidney C. Smith,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Jonathan L. Halperin,Loren F. Hiratzka,Alice K. Jacobs,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +27 more
TL;DR: This document summarizes current capabilities, research and operational priorities, and plans for further studies that were established at the 2015 USGS workshop on quantitative hazard assessments of earthquake-triggered landsliding and liquefaction.
Journal ArticleDOI
ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure).
TL;DR: The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines regularly reviews existing guidelines to determine when an update or full revision is needed.
Journal ArticleDOI
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation
Sharon A. Hunt,William T. Abraham,Marshall H. Chin,Arthur M. Feldman,Gary S. Francis,Theodore G. Ganiats,Mariell Jessup,Marvin A. Konstam,Donna Mancini,Keith Michl,John A. Oates,Peter S. Rahko,Marc A. Silver,Lynne W. Stevenson,Clyde W. Yancy +14 more
TL;DR: Theodore G. Feldman, MD, PhD, FACC, FAHA, Chair as mentioned in this paper, Chair, Chair of FAHA 2015, 2016, 2017, 2018, 2019, 2019
Journal ArticleDOI
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
TL;DR: The medical profession should play a central role in evaluating the evidence related to drugs, according to a report by the World Health Organization and the European Medicines Agency.
References
More filters
Journal ArticleDOI
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Milton Packer,Joseph R. Carver,Richard J. Rodeheffer,Russell J. Ivanhoe,Robert DiBianco,Steven M. Zeldis,Grady H. Hendrix,William J. Bommer,Uri Elkayam,Marrick L. Kukin,George I. Mallis,J. Sollano,James A. Shannon,P. K. Tandon,David L. DeMets +14 more
TL;DR: The findings indicate that despite its beneficial hemodynamic actions, long-term therapy with oral milrinone increases the morbidity and mortality of patients with severe chronic heart failure.
Journal ArticleDOI
Double-Blind Placebo-Controlled Study of Ibopamine and Diagoxin in Patients With Mild to Moderate Heart Failure: Results of the Dutch of the Ibopamine Multicenter Trial (DIMT)
Dirk J. van Veldhuisen,Arie J. Man in't Veld,Peter H. J. M. Dunselman,Dirk J. Lok,Henk J.M. Dohmen,J.Cees Poortermans,A.J. Withagen,W.Hans Pasteuning,Jan Brouwer,Kong I. Lie +9 more
TL;DR: Ibopamine and digoxin both inhibit neurohumoral activation in patients with mild to moderate chronic heart failure and appear to be related to the degree of left ventricular dysfunction.
Journal ArticleDOI
Treatment of severe heart failure: quantity or quality of life? A trial of enoximone. Enoximone Investigators.
Alan J. Cowley,A M Skene +1 more
TL;DR: In patients with severe heart failure who remain incapacitated despite conventional treatment enoximone reduced survival but had a beneficial effect on the quality of life, drugs that improve symptoms in severe end stage heart failure should not be discarded lightly.
Journal ArticleDOI
Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
Barry M. Massie,M R Berk,S C Brozena,Uri Elkayam,J F Plehn,Marrick L. Kukin,Milton Packer,B E Murphy,Gerald W. Neuberg,Richard M. Steingart +9 more
TL;DR: Results indicate that additional symptomatic benefit can be attained by adding flosequinan to a therapeutic regimen already including a converting enzyme inhibitor, and potential adjunctive agent in the management of severe congestive heart failure.
Journal ArticleDOI
Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
Michel F. Rousseau,Michel F. Rousseau,Michel F. Rousseau,Marvin A. Konstam,Marvin A. Konstam,Marvin A. Konstam,Claude R. Benedict,Claude R. Benedict,Claude R. Benedict,Julian Donckier,Julian Donckier,Julian Donckier,Laurence Galanti,Laurence Galanti,Laurence Galanti,Jacques Melin,Jacques Melin,Jacques Melin,Debra Kinan,Debra Kinan,Debra Kinan,Sylvie A. Ahn,Sylvie A. Ahn,Sylvie A. Ahn,Jean-Marie Ketelslegers,Jean-Marie Ketelslegers,Jean-Marie Ketelslegers,Hubert Pouleur,Hubert Pouleur +28 more
TL;DR: The neurohormonal control provided by an angiotensin-converting enzyme inhibitor is reduced in a large subset of patients during prolonged therapy; ibopamine appears to be a potentially useful drug to improve neuroh hormonal control in this setting.
Related Papers (5)
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure
Jay N. Cohn,Gary R. Johnson,Susan Ziesche,Frederick R. Cobb,Gary S. Francis,Felix E. Tristani,Raphael F. Smith,W. Bruce Dunkman,Henry S. Loeb,Maylene Wong,Geetha Bhat,Steven Goldman,Ross D. Fletcher,James J. Doherty,C. Vincent Hughes,Peter E. Carson,Guillermo Cintron,Ralph Shabetai,Clair Haakenson +18 more